About Us. Your Needs? Next Steps

Transcription

1 1

2 About Us ü Business Development Your Needs? Next Steps 2

3 S. Jordan Associates (SJA) is a management consul6ng firm dedicated to: About Us Emerging Growth Companies, Sell Side Assis6ng early- stage/growth companies accelerate therapeu6c, medical device, and healthcare informa6on technology (HIT) development programs via business development (licensing), private placements and exits (M&A) Empowering search and evalua6on teams source premium deal flow globally via Financial Technology (FinTECH) BioPharma, Medical Devices, Medtech; Investors Buy Side

4 OVERVIEW ScoR Jordan Accomplished life sciences execu6ve with over 25+ years of experience nego6a6ng strategic corporate alliances, securing interna6onal licensing agreements, building na6onal sales teams, and contribu6ng to successful product development, approval, and launch Cross func6onal experience including leadership roles in sales & marke6ng, licensing, finance, and business development Level II Candidate in the Chartered Financial Analyst (CFA) Program and holds Series 7, 66, 63 & 31 Cer6fica6ons CAREER HIGHLIGHTS Launched the world s first equity crowdfunding placorm sponsored by a stock exchange (Singapore, SGX), and venture capital firm (Clearbridge Accelerator), CapBridge hrp:// Founder of Healthios investment marketplace, HealthiosXchange, hrp:// ; raised over $150 million for private emerging growth healthcare companies from Signed a licensing agreement with Nippon Kayaku, a leading Japanese pharmaceu6cal company with over $1.2 billion in revenues, for the rights to IL13- PE38QQR (fusion protein - glioblastoma mul6forme) on December 28, NeoPharm received a $3 million upfront payment with poten6al milestones of $25 million Nego6ated a licensing agreement with Wyeth- Ayerst for the rights to NeoPharm s LE raf AON (an6sense) in

5 FINANCIAL TECHNOLOGY (FINTECH) Why SJA is Different? Technology BANKING: PRIVATE PLACEMENTS: In a recent lerer to shareholders, JP Morgan CEO Jamie Dimon warned of growing compe66on for Wall Street in the form of tech start- ups. Silicon Valley is coming, Dimon said in the lerer, which touched on technologies as varied as mobile payments, bitcoin and peer- to- peer lending. There are hundreds of start- ups with a lot of brains and money working on various alterna6ves to tradi6onal banking, the CEO warned. Alterna6ve Finance is a new phenomenon, and it is taking the world by storm. With over 1,250 crowdfunding placorms worldwide, this new model of collabora6ve funding is breaking boundaries and defying the status quo as to how issuers source capital. In light of this paradigm ship and plethora of placorms, we perceived the need to develop an alterna6ve finance aggregator that would instantaneously display quality private investment opportuni6es from curated placorms, all in one centralized marketplace. Democra6sing Finance, Alterna6ve Finance Demys6fied, DealIndex, July 2015 COMPANIES Source Licensing Partners ONLINE INVESTMENT MARKETPLACES Access to Deal Flow BIOPHAMA, MEDICAL DEVICES, MEDTECH; INVESTORS Business development, private inves6ng, and M&A are moving online while alternabve finance started off as seed stage endeavor, more recently plagorms have begun to emerge at different stages in the funding cycle disrupbng tradibonal insbtubons Online global inves6ng reached $16.4B in 2014 over 1,250 crowdfunding plagorms worldwide Alterna6ve finance is drawing more established issuers originally seen as a solubon to the long- standing funding gap for early stage companies appearing in the wake of the 2008 financial crisis, the ability for issuers to raise capital more quickly and at a lower cost than would otherwise be possible at tradibonal insbtubons Alterna6ve finance is removing informa6on barriers and informabon inefficiencies existing in the private market, opening funding conduits and channeling global liquidity

6 FinTECH Financial Technology >3,300 members Accredited Investors, Early- Stage/Growth Company Execu6ves, Investment Professionals, Strategic Buyers 700 Ac6ve healthcare companies in 46 Market Sectors Seeking Licensing Partners, Financings, and/or Exits Sponsors S. Jordan Associates and Healthios, Chicago- Based Healthcare Investment Bank The World s Premier Direct Inves6ng Placorm Sponsored by the Singapore Stock Exchange (SGX), Venture Capital Firm - Clearbridge Accelerator, and HealthiosXchange SGX - Raise, Capital for Small- Medium Size Enterprises (SME), Fund Alloca6on, Shares depository ( IPO On Ramp ) Launching 9/15 U.S. and Europe Asia Pacific

7 Business Development + Strategic Advisory + Private Placements = Comprehensive Suite of Services Devoted to Maximizing Shareholder Value What SJA Can Do For You? Business Development Partner with SJA - Execute Licensing Agreements with Large BioPharma, Medical Devices, HIT Companies Private Placements Collaborate with SJA and Healthios Sourcing Capital From Ins6tu6onal and Alterna6ve Investors Strategic Advisory Hire SJA as Your Internal Investment Banking Team Acquiring Products/Companies

8 S. Jordan Associates: Business Development Business Development it s a widely- held belief that a cri4cal element of excep4onal R&D organiza4ons in the future will be crea4ve BD engagement. In short, great BD and R&D are becoming synonymous with each other. Bruce Booth, External Innova6on: Force Mul6plier for R&D, Forbes, 6/26/15

9 About Us BUSINESS DEVELOPMENT SERVICES 9

10 SJA Services: Business Development BUSINESS DEVELOPMENT: Established track record of assis6ng early- stage/growth companies structure licensing and co- development/jv agreements with major BioPharma, Medical Device, Medtech and Healthcare Services companies ( Strategics ), including: 1. Understanding the Process When Should I Partner? Am I Ready to Partner? Define Goals Including Timelines AlternaBve Corporate Structures (LLC, C- Corp) AlternaBve Licensing Structures (Early Pharma Structured Buyouts) 2. Core Document Prepara6on ExecuBve Summary Management PresentaBon Financial ValuaBon/Modeling 3. Iden6fy, Communicate, Manage Licensing Agreements w/strategics: Iden&fy SJA Rolodex and Data AnalyBcs (HealthiosXchange, Capbridge) Communicate Online ( , social media), Offline (partnering events, one- on- one s) Manage/Due Diligence 4. Nego6a6on Term Sheets Full Agreement 5. Closing, Win SJA Track Record: Supervised business development ini6a6ves for IRX Therapeu6cs leading to collabora6on with a leading pharmaceu6cal company in 2014 Advised Advanced Life Sciences on securing a licensing partner for the Company s next- genera6on an6bio6c in Community Acquired Pneumonia (CABP), Restanza TM /cethromycin, resul6ng in a LeRer of Intent (LOI) from a major Italian pharmaceu6cal company (2013) Signed a licensing agreement with Nippon Kayaku, a leading Japanese pharmaceu6cal company with over $1.2 billion in revenues, for the rights to IL13- PE38QQR (fusion protein - glioblastoma mul6forme) on December 28, NeoPharm received a $3 million upfront payment with poten6al milestones of $25 million Iden6fied opportuni6es for out- licensing NeoPharm s proprietary liposome drug delivery technology, NeoLipid TM. Signed licensing distribu6on agreements with Nippon Gene6cs and Avan6 Polar Lipids in Nego6ated a licensing agreement with Wyeth- Ayerst for the rights to NeoPharm s LE raf AON (an6sense) in 2002

11 SJA Services: Business Development CREATIVE DEAL STRUCTURING - EXTERNAL R&D: 1. Direct External Innova6on Models - Partnering Around a Specific Company/Project Venture Co- Crea6on Large Pharma/Medical Device parbcipate with venture capital firms in early moments of launching a company Built- to- Buy Deals Asset- centric drug discovery startups, with pre- defined acquisibon rights at Development Company nominabon Broad Company Accelera6ng R&D Collabora6ons Upfront capital in exchange for pre- specified product rights (e.g. Agios/ Celgene) 2. Fund Related Porcolio Approaches Large Pharma/Medical Device Expand Reach and Exposure to Innova6on Corporate Venture Capital Syndicate partners of choice in the early- stage arena Limited Partnership Commitments To established venture funds Op6on Funds Either in- house funds with product rights or LP- relabonships where Pharma/Medical Device gains direct rights to opbon- in or access the underlying investments in the porgolio 3. Open Innova6on Models Academic Partnerships Consor6a- based Pre- Compe66ve Internal Capabili6es Sharing Future of Innova6on in the life sciences will be defined by a converging R&D ecosystem that brings larger BioPharma companies, young biotech's, VC s and academia together in new collabora6ve models. Bruce Booth, External Innova6on: Force Mul6plier For R&D, Forbes, 6/26/15

12 Business Development: Research RESEARCH 12

13 Business Development: Top 10 Drugs 10 Drugs that could transform the industry (Jan 2014) While the list itself is interes4ng, and each drug could be a blockbuster, I wanted to call ahen4on to something the Goldman report and many others haven t highlighted directly: the instrumental and essen4al role of smart business development deal- making underpinning these projects. By my quick review, it appears as though ~75% of these drugs originated at firms different from the company that owns them today either via licensing deal or via corporate acquisi4ons. Savvy business development and corporate development strategies drove the bulk of the list. Bruce Booth, Transforma6onal Late Stage Drugs Delivered Through Deal Making, Forbes, 3/21/14

14 Business Development: Top 10 Drugs 10 Drugs that could transform the industry (Jan 2014) High Poten6al Pipeline Drugs That Could Transform the Industry it s no wonder that every big drug company wants to be Partner of Choice with smaller innovators. Nearly every pharma has hired consultants at some point to help it posi4on its BD strategy more effec4vely. 2/3rd s of the valua6on of the industry s late stage pipelines is from externally derived programs Bruce Booth, Transforma4onal Late Stage Drugs Delivered Through Deal Making, Forbes, 3/21/14

15 LANDSCAPE & TRENDS Business Development: Trends while the number of VC- backed M&A exits is in line with prior years (~25 per year), the value both in terms of upfront and full biobuck (~milestones) poten6al have reached new highs, topping over $5 and $8 billion, respec6vely. the average values per deals are steadily escala6ng even though the average invested capital required to get there has remained steady. these trends have led to a very robust and posi6ve return trend. Return mul6ples have almost tripled since on overall deal mul6ples, and have more than doubled on the upfront mul6ples. Bruce Booth, Data Snapshot: VC- Backed BioPharma M&A 2014, Forbes, 2/3/15

16 Business Development: External R&D Innova6on EXTERNAL R&D INNOVATION.private VC- funded biotech is a 6ny frac6on of the scale of the bigger BioPharma part of the sector in every major financial dimension. Small percen6le changes to a Big BioPharma company s market can swamp the scale of the biotech sector..because of the scale difference, even small changes in the resource alloca6on prac6ces within large BioPharma companies coffer has the poten6al to drama6cally alter the biotech ecosystem. Assume these big BioPharma companies channeled just ~5% of their balance sheet cash into private biotech companies this capital flow would fully fund the en6re VC- backed biotech sector for a year (~50 companies)..this differen6al in size makes Pharma s increasing 'externaliza6on' of their R&D func6ons (via partnerships and M&A) a significant financial 'buffer against the cyclic ups and downs of the public capital markets. Bruce Booth, Data Snapshot: Dwarfed By Big Pharma, Biotech by The Numbers, Forbes 2/16/15

17 CASE STUDY: EXTERNAL R&D INNOVATION Business Development: Celgene/Agios SUMMIT, N.J. & CAMBRIDGE, Mass.- - April 15, Celgene Corpora6on (NASDAQ: CELG) and Agios Pharmaceu6cals Inc., a privately- held biotechnology company, today announced the forma6on of a global strategic collabora6on focused on targe6ng cancer metabolism. The goal of the collabora6on is to discover, develop, and deliver novel disease- altering therapies in oncology based on the transforma6onal science of Agios innova6ve cancer metabolism research placorm. This placorm is based on the concept that targe6ng key metabolic enzymes unique to rapidly prolifera6ng cancer cells can starve the cancer. Terms of the Agreement: Under the terms of the agreement, Agios will receive a $130 million upfront payment, including an equity investment In return, Celgene receives an ini6al period of exclusivity during which it has the op6on to develop any drugs resul6ng from the Agios cancer metabolism research placorm, in addi6on, Celgene may extend this exclusivity period through addi6onal funding If successful, Agios would receive substan6al regulatory, clinical and commercial milestones Agios will lead discovery and early transla6onal development for all cancer metabolism programs Celgene has an exclusive op6on to license any resul6ng clinical candidates at the end of Phase I, and will lead and fund global development and commercializa6on of licensed programs On each program, Agios may receive up to $120 million in milestones as well as royal6es on sales, and may also par6cipate in the development and commercializa6on of certain products in the US Celgene s $120M into Agios discovery stage story was a surprise then, but looks prery smart now. It s equity ownership alone nearly paying for the deal, not to men6on product rights." "A big part of how Agios have done this is via crea6ve business development; their landmark deal with Celgene allowed them to scale with non- dilu6ve funding during a cri6cal 6me for the company, which opened up mul6ple op6ons (and new disease areas to the startup) If well structured, less dilu6ve financing mechanisms via crea6ve collabora6ons can catalyze significant value crea6on and op6onality for young companies Bruce Booth, Biopharma M&A: Capital Efficiency Drives Returns, Forbes, 5/15/15

18 Business Development: Capital Efficiency Capital Intensity Total Amount of Equity Investment Required to Create a Value Inflec6on Capital Efficiency: Most amount of value generated per unit dollar ($) invested CAPITAL EFFICIENCY Cost of Capital Rate of Return New Investors Will Demand Ini6ally raised a $33M Series A Round (~Third Rock Ventures) at $2.73/share Created enough scien6fic progress to partner with Celgene bringing $120M in largely non- dilu6ve funding (and some Series B equity) Celgene deal drove the momentum to raise $75M+ Series C at $13.50/share Public, raising $106M at $18/share Agios (AGIO) now trading > $80/share Bruce Booth Framing Up Capital Efficiency in Early Stage Biotech, Forbes, 7/17/14 A very clear inverse correla6on exits between investor returns and equity capital deployed.m&a values don t move up propor6onally with invested capital. Returns from acquisi6on- based exits frequently go down with increasing amount of funding. Bruce Booth BioPharma M&A: Capital Efficiency Drives Returns, Forbes 5/15/15

19 S. Jordan Associates SUMMARY 19

20 S. Jordan Associates Business Development Private Placements Strategic Advisory HealthiosXchange is affiliated with Healthios Capital Markets, LLC, a registered (FINRA, SEC) registered broker dealer

21 S. Jordan Associates (SJA) is a management consul6ng firm dedicated to assis6ng early- stage/growth companies accelerate therapeu6c, medical device, and medtech development programs. Leveraging over 25 years of experience in pharma, biotech, investment banking, and FinTECH (founder of the premier online investment portal, HealthiosXchange), SJA has established a strong track record of execu6ng licensing agreements, private placements and exits (M&A) on behalf of clients. S. Jordan Associates 47 W. Division Street Chicago, IL hnp://sjordanassociates.com/ Healthios/HealthiosXchange 1101 Skokie Northbrook, IL hnp://

22 Melissa Newcomer is a clinical trial operabons expert with over 16 years of industry experience including managing Phase I- IV studies in both drug and medical device trials. Melissa has a deep understanding of clinical trials from both a Sponsor and Contract Research OrganizaBon (CRO) perspecbve. Having direct oversight of project progress, including pabent recruitment and retenbon, risk management, audit- readiness, as well as financial and team management, Melissa is experienced in handling standard clinical operabons execubon. AddiBonally, Melissa provides a level of transparency and cohesiveness amongst cross- funcbonal groups and stakeholders. hrps:// TEAM Dan Verakis is an accomplished internabonal business consultant, markebng expert and technology entrepreneur with more than 20 years of corporate experience in delivering and supporbng strategic business and operabons objecbves. His experbse includes business strategy development and execubon, leadership training, investor relabons, and execubng healthcare, scienbfic, consumer branded, crisis management, change management communicabons and markebng programs for Fortune 500 companies. hrps://

23 TEAM David Herrera started his career within the Structured Finance group of XL Capital Ltd, a Bermuda- based Reinsurance firm, as a Guaranteed Investment Contract (GIC) underwriter; where he underwrote, priced, and performed due diligence on over $1BN in deal- flow on a monthly basis from 2005 to As a Financial Analyst within the Private Placements and Joint Ventures group at Inland American Real Estate Investment Trust, Inc. David oversaw and managed a $1.3BN commercial real estate development fund/joint venture through Chapter 11 bankruptcy, restructuring and the emergence thereof. In his capacity as Second Vice President of the Public and Structured Finance group at Northern Trust CorporaBon, David was in charge of P&L oversight and performed financial modeling, structuring, pricing, and transacbonal execubon on interest- rate derivabve trades.

24 Thank You 24